20/20 GeneSystems

Biomarker Testing for Multi-Cancer Early Detection and Longevity

https://wefunder.com/2020.gene.systems

Total raised on Wefunder: 542161

Total investors: 360

Quick facts

  • 20/20 is a leader in the Multi-Cancer Early Detection (MCED) market, expected to reach $50B.
  • VC investments: Wako (Fujifilm), PingAn, Calvert (Morgan Stanley), MD Venture Fund, Brevet, Keiretsu
  • Secured $5M+ in research grants/contracts from National Cancer Institute (NCI) and others.
  • Ranked #134 on 2023 Inc. 5000 list of the “Fastest Growing Companies in America” (#1 in Maryland).
  • Utilize technology from Abbott Diagnostics and Roche Diagnostics for our MCED solutions.
  • Sales volume from our cancer testing grew 2.2X from 2022 to 2023.
  • Multiple issued or allowed patents in the U.S. and East Asia (available in Downloads section).
  • Our team has 100+ years of combined biotech/life science experience. Board chair sold BioDx to Opko.

Team profiles

Featured investor profiles

20/20 GeneSystems

Biomarker Testing for Multi-Cancer Early Detection and Longevity

Funded badge
Last Funded February 2025

$542,161

raised from 360 investors

What Investors Say

LEAD INVESTOR
Invested $12,500 this round + $55,000 previously
Early investment in 20/20 GeneSystems represents my expectation to benefit from 20/20’s offering and focus on the newest paradigm in cancer detection. For most cancers, the paradigm for effective long-term treatment and disease remission relies heavily on early detection. Multiple cancer early detection testing (MCED) will become standard of care for cancer detection if the test detects a broad range of cancer types, if the predictive power of the test is sufficiently high (the likelihood that cancer is present), and if the test cost is sufficiently low (to justify routine testing). 20/20 GeneSystems markets an MCED test that meets these criteria and represents an early entry into the huge cancer diagnostics market. The new partnerships with the MD Anderson Cancer Center and other research centers promise to significantly improve the predictive power of 20/20’s MCED test across a range of cancers, jumpstart acceptance and adoption of MCED testing, and solidify a competitive advantage for the Company.
What People Say